Clinical trials: Solid Tumors, completed
Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
RATIONALE: Topical sunscreen may be effective in preventing skin rash caused by treatment with drugs such as erlotinib or cetuximab.
- Trial name
- NCT00362986
- Testing
- sunscreen
- Where
- 208 sites in United States
- Volunteers
- 116 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Rhabdomyosarcoma, Osteosarcoma
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Patients with relapsed solid tumors such as sarcomas and neuroblastoma have a poor survival, generally < 20%. There is an urgent need for new treatments that are safe and effective.
- Conditions
- Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT00931931
- Testing
- HSV1716
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Timothy Cripe
Solid Tumor, Adult
Study of DF9001 in Patients With Advanced Solid Tumors
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases.
- Trial name
- NCT05597839
- Testing
- DF9001, KEYTRUDA® (pembrolizumab)
- Where
- 17 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dragonfly Therapeutics
Cancer
Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)
This is a Phase I clinical trial evaluating the safety and tolerability of escalating doses of vintafolide (EC145) in participants with relapsed or refractory advanced tumors.
- Trial name
- NCT00308269
- Testing
- Vintafolide IV Bolus, Vintafolide IV Infusion
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Endocyte
B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled design.
- Trial name
- NCT04836195
- Testing
- PCLX-001 - 20mg, PCLX-001 - 40mg, PCLX-001 - 70mg
- Where
- 4 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Pacylex Pharmaceuticals
Melanoma, Metastases
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new…
- Trial name
- NCT00099970
- Testing
- M200 (volociximab) in Combination with Dacarbazine (DTIC)
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- PDL BioPharma, Inc.
Cancer
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
A multicenter, non-randomized, placebo-controlled, single dosing schedule, subject-blinded study to evaluate the effect of GSK1120212 on the electrical activity of the heart as compared to placebo in subjects with solid tumor…
- Trial name
- NCT01658553
- Testing
- GSK1120212
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Leukemia, Lymphoma
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
The study team will compare hospital length of stay (LOS) and attributable length of stay (ALOS, the LOS attributable to CRI), in a randomized, un-blinded prospective trial utilizing short-dwell ethanol-lock therapy (ELT) (4…
- Conditions
- Leukemia, Lymphoma, Blood Disorders, Solid Tumors
- Trial name
- NCT02095951
- Testing
- Ethanol lock therapy (ELT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Michigan
Unspecified Adult Solid Tumor, Protocol Specific
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NKTR-214 (NCT02869295)
- Testing
- NKTR-214
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Nektar Therapeutics
Cancer, Solid Tumor
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
This is a Phase I, multi-center, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients with Solid Tumors.
- Conditions
- Cancer, Solid Tumor, Metastatic Colorectal Cancer (mCRC)
- Trial name
- NCT01705002
- Testing
- Promitil, Capecitabine, Bevacizumab
- Where
- 4 sites in Israel
- Volunteers
- 88 people
- Sponsor
- Lipomedix Pharmaceuticals Inc.
Solid Tumors, Ototoxicity
Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy
Platinum based chemotherapy (mainly Cisplatin) is known to cause a variety of adverse effects, including Ototoxicity and nephrotoxicity.
- Trial name
- NCT06553157
- Testing
- Statin
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Minia University
Advanced Solid Tumors, Lymphomas
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
The purpose of this study was to determine the safety profile, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to characterize the pharmacokinetic (PK) profile of alisertib twice daily (BID) dosing for 7 days…
- Trial name
- NCT01512758
- Testing
- Alisertib
- Where
- Singapore
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumours
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
This is a 3 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating and the effect of olaparib on QT…
- Trial name
- NCT01921140
- Testing
- Olaparib tablets, Pharmacokinetic sampling, Dietary Fasted
- Where
- 12 sites in Belgium, Denmark and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
RATIONALE: Providing information that is tailored to answer patients' questions about clinical trials may help patients with cancer decide to enroll in a clinical trial.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00750009
- Testing
- educational intervention
- Where
- 4 sites in United States
- Volunteers
- 583 people
- Sponsor
- Case Comprehensive Cancer Center
Solid Tumor, Adult
Impact of ICU on the Quality of Life in Cancer Patients
This is an observational, prospective, monocentric, case-control study. Investigators aim to compare the quality of life and oncological treatment strategy in cancer patients admitted or not in ICU.
- Trial name
- QdV-ONCOREA (NCT04310033)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Grenoble
Advanced Solid Tumors, Head and Neck Cancer
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- FPA008-003 (NCT02526017)
- Testing
- Cabiralizumab, Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 313 people
- Sponsor
- Five Prime Therapeutics, Inc.
Neoplasms, Malignancies
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
The purpose of this study is to find the safest dose level of an approved drug, carfilzomib, in solid tumors when given over a different period of time than normally used.
- Trial name
- NCT02257476
- Testing
- Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Solid Tumor, Breast Cancer
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
This first-in-human, open-label, multicenter, Phase Ia/Ib, adaptive, multiple ascending-dose study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of…
- Conditions
- Solid Tumor, Breast Cancer, Cancer of Head and Neck
- Trial name
- NCT02627274
- Testing
- RO6874281, Trastuzumab, Cetuximab
- Where
- 26 sites in United States, Belgium and 7 more
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer, Solid Tumor Cancer
Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application
The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving…
- Conditions
- Cancer, Solid Tumor Cancer, Chemotherapy
- Trial name
- ROSA App (NCT07218874)
- Testing
- Mobile Symptom Monitoring and Alert App
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.